Generic Name:
sodium phenylbutyrate and ursodoxicoltaurine
Project Status:
Complete
Therapeutic Area:
Amyotrophic lateral sclerosis (ALS)
Manufacturer:
Amylyx Canada
Brand Name:
Albrioza
Project Line:
Reimbursement Review
Project Number:
SR0711-000
NOC Status at Filing:
Pre NOC
Details
Manufacturer Requested Reimbursement Criteria1:
For the treatment of patients with amyotrophic lateral sclerosis (ALS).
Submission Type:
Initial
Fee Schedule:
Schedule A
Indications:
For the treatment of patients with amyotrophic lateral sclerosis (ALS).
Recommendation Type:
Reimburse with clinical criteria and/or conditions
Final Recommendation:
- The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.